Risk of bleeding with dabigatran in atrial fibrillation.
about
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationThe evolution of anticoagulant therapyNovel antidotes for target specific oral anticoagulantsLong-term prescribing of new oral anticoagulantsDOACs - advances and limitations in real worldRisk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational StudiesDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced ageDirect oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by AgeComparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants.Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort studyNon-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwideClinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.Anticoagulation in Atrial Fibrillation - Current ConceptsPredictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial FibrillationComparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort stuWho Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory ModelsThe association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies.Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians.Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.Dabigatran for the prevention and treatment of thromboembolic disorders.Dose tailoring of dabigatran etexilate: obvious or excessive?Time to reconsider dabigatran 110 mg in the USA.Trends in Warfarin Monitoring Practices Among New York Medicare Beneficiaries, 2006-2011.Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding.Evaluation of bleeding in patients receiving direct oral anticoagulants.High risk use of OTC NSAIDs and ASA in family medicine: A retrospective chart review.Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.New Oral Anticoagulants and Their Reversal Agents.Review And Insights Into The Bleeding Mechanism Incited By Antithrombotic Therapy: Mechanistic Nuances Of Dual Pro-Hemorrhagic Substrate Incorporating Drug-Induced Microvascular Leakage.
P2860
Q26749141-0B0D5A68-5BE1-42FB-AF69-B26AA434187BQ26771859-CBF1BC17-8FCC-464B-BDE8-EA73106A0182Q26784125-6D73AF4A-DA9C-44A3-8618-F283874D6619Q28069821-4DCB3EF0-7E51-4649-9902-92A55FA71A8BQ28070132-7E70994F-888A-465B-84F0-741387FFFC71Q28078747-DB4A1E73-DB9C-430D-A40B-87B10E689C81Q28079930-FE0A2558-7FEA-4832-9539-8DAE2BB44FE8Q30979197-97EC0F00-5B98-4040-8F0B-70D000B7C9A7Q30994474-413F46E3-AF5E-43EC-8F91-C9DA5CA45E05Q31131255-0DFEC37B-99A8-4130-81BB-ED028E404B4EQ34469002-527DCCFF-A675-449A-A04D-D74A3C42EA02Q35475000-0FE3DE8D-3CAB-44FE-B3F2-5AA8436F8390Q35550883-D32031BC-A271-4A9A-946B-E62851874DF5Q35798597-55DF3EB2-79AE-452D-8780-F749E0FCF665Q36085794-3CC916F8-74AD-4DA8-B44F-CFE12CEBFDCBQ36100271-1FDBEAE9-A69E-45C6-A22F-2BB6B7C617EBQ36232280-B0F9B0B5-50D3-49D1-91F6-1E1B56D434AFQ36356624-563F6F3E-B390-4C28-99CD-B0D23114E7B8Q36458853-DC0E816A-6FA7-4B85-9C36-9B3B3B164928Q36571742-98D26B33-A70C-4F62-A6D8-E291580741E3Q36618123-E3D6E6C4-56B1-4EB7-9D8F-209F5C8752B5Q36657598-01EF25C3-084A-40B3-9B35-28F291CB1D10Q36947797-991DCF65-F9C7-424E-8356-3B5068C5A33DQ37004184-92524BB9-F89B-4022-9B65-34111A1D04EDQ37030683-F702372F-199C-4591-97FF-1F8BF9A8B0DFQ37076243-801E82B1-F6F8-421F-B385-F367771E40FEQ37613761-77619138-ACF5-4638-AC31-AB454000FBC2Q37672517-6EAE756D-784A-4313-8CF0-3021043E3056Q38406325-48B70332-196E-433C-AD00-C15DC6FD4E19Q38494667-2361E1FE-4041-4DB0-8418-CD9712E5E2D5Q38526044-2FE2F265-A9F4-4273-A41B-74B71F564739Q38551723-83A2F80D-72D8-4F30-99EF-FA0992A4BCA0Q38597796-F600186B-381D-471C-9BDF-7063D63804CCQ38598970-858CC8A0-F4CE-4C01-A269-0146EC094AB3Q38693356-A96F01BA-5087-4F79-8EF3-04051676AB0DQ38713953-DF14BC3E-EE5F-4B87-B7AF-7C8308DC6F23Q38723869-6EDA0651-87A0-4FB0-B4AB-C39A3CF1057AQ38889501-F19FAD87-8F65-496B-AB73-733FBDCBEB14Q38970532-C383DD68-5F33-46D9-B00D-1E8E16FD3178Q39037122-808A5A79-3C0F-4E67-B7FC-1E01579C497F
P2860
Risk of bleeding with dabigatran in atrial fibrillation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Risk of bleeding with dabigatran in atrial fibrillation.
@en
Risk of bleeding with dabigatran in atrial fibrillation.
@nl
type
label
Risk of bleeding with dabigatran in atrial fibrillation.
@en
Risk of bleeding with dabigatran in atrial fibrillation.
@nl
prefLabel
Risk of bleeding with dabigatran in atrial fibrillation.
@en
Risk of bleeding with dabigatran in atrial fibrillation.
@nl
P1476
Risk of bleeding with dabigatran in atrial fibrillation.
@en
P2093
Antonio Piñera
Seo Hyon Baik
P356
10.1001/JAMAINTERNMED.2014.5398
P577
2015-01-01T00:00:00Z